Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Cash from Financing Activities (2022 - 2026)

Core Laboratories filings provide 5 years of Cash from Financing Activities readings, the most recent being -$457000.0 for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 89.8% to -$457000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$27.2 million, a 41.26% increase, with the full-year FY2025 number at -$31.3 million, up 31.99% from a year prior.
  • Cash from Financing Activities hit -$457000.0 in Q1 2026 for Core Laboratories, up from -$7.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $6.1 million in Q1 2023 to a low of -$19.4 million in Q4 2024.
  • Median Cash from Financing Activities over the past 5 years was -$6.0 million (2023), compared with a mean of -$7.6 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 32464.29% in 2024 and later skyrocketed 89.8% in 2026.
  • Core Laboratories' Cash from Financing Activities stood at -$12.6 million in 2022, then crashed by 46.97% to -$18.5 million in 2023, then dropped by 4.84% to -$19.4 million in 2024, then surged by 63.24% to -$7.1 million in 2025, then surged by 93.58% to -$457000.0 in 2026.
  • The last three reported values for Cash from Financing Activities were -$457000.0 (Q1 2026), -$7.1 million (Q4 2025), and -$16.5 million (Q3 2025) per Business Quant data.